Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA® (fruquintinib) 1mg/5mg capsules in Japan ...

Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate ... fruquintinib), a selective oral inhibitor of vascular endothelial growth ...

“CSFR is increased in lesions in MS and EAE [experimental autoimmune encephalomyelitis].” Fexagratinib, which was previously ...

After antibody-drug conjugate (ADC) specialist Seagen was sold to Pfizer last year for a whopping $43 billion, former CEO David Epstein said he was looking to “hopefully make new drugs somewhere ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.